OUTLOOK THERAPEUTICS INC (OTLK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
OUTLOOK THERAPEUTICS INC stock (OTLK) is currently trading at $0.21. OUTLOOK THERAPEUTICS INC PS ratio (Price-to-Sales) is 129.14. Analyst consensus price target for OTLK is $4.83. WallStSmart rates OTLK as Sell.
- OTLK PE ratio analysis and historical PE chart
- OTLK PS ratio (Price-to-Sales) history and trend
- OTLK intrinsic value — DCF, Graham Number, EPV models
- OTLK stock price prediction 2025 2026 2027 2028 2029 2030
- OTLK fair value vs current price
- OTLK insider transactions and insider buying
- Is OTLK undervalued or overvalued?
- OUTLOOK THERAPEUTICS INC financial analysis — revenue, earnings, cash flow
- OTLK Piotroski F-Score and Altman Z-Score
- OTLK analyst price target and Smart Rating
OUTLOOK THERAPEUTICS INC
📊 No data available
Try selecting a different time range
Smart Analysis
OUTLOOK THERAPEUTICS INC (OTLK) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
OUTLOOK THERAPEUTICS INC (OTLK) Key Strengths (2)
Keeps $1116 of every $100 in revenue after operating costs
Revenue surging 658.00% year-over-year
Supporting Valuation Data
OUTLOOK THERAPEUTICS INC (OTLK) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 129.1x annual revenue
Very expensive at 10.2x book value
Very low institutional interest at 8.22%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
OUTLOOK THERAPEUTICS INC (OTLK) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth. Profitability is solid with Operating Margin at 1116.00%. Growth metrics are encouraging with Revenue Growth at 658.00%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (129.14), Price/Book (10.19) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -3.65%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -3.65% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 658.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OTLK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OTLK's Price-to-Sales ratio of 129.14x sits near its historical average of 118.17x (83th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 95% below its historical high of 2350.57x set in Oct 2024, and 4545% above its historical low of 2.78x in Sep 2023. Over the past 12 months, the PS ratio has compressed from ~570.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for OUTLOOK THERAPEUTICS INC (OTLK) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
OUTLOOK THERAPEUTICS INC is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 205,700 with 658% growth year-over-year.
Key Findings
Revenue growing at 658% YoY, reaching 205,700. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -0.01 indicates a conservative balance sheet with 9M in cash.
Free cash flow is -14.9T, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can OUTLOOK THERAPEUTICS INC maintain 658%+ revenue growth, or will competition slow it down?
Debt management: total debt of 233.1B is significantly higher than cash (9M). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact OUTLOOK THERAPEUTICS INC.
Bottom Line
OUTLOOK THERAPEUTICS INC is a high-conviction growth story with revenue accelerating at 658% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About OUTLOOK THERAPEUTICS INC(OTLK)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.